Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | PRNP | P04156 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14493573 | 0.77 | CYP3A4 (0.35) | NQO2PRNPNPSR1LMNAHPGD | |
| SCHEMBL3844867 | 0.77 | CYP1A2 (0.46) | LMNAALDH1A1MAPT | |
| SCHEMBL18630364 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL14493595 | 0.74 | CYP3A4 (0.39) | NQO2LMNAHPGDHTTALDH1A1 | |
| SCHEMBL6832989 | 0.74 | MAOA (0.42) | NQO2HTT | |
| SCHEMBL27384772 | 0.72 | LMNA (0.36) | NQO2PRNPNPSR1LMNAHPGD | |
| SCHEMBL558700 | 0.72 | NOS3 (0.45) | NQO2LMNAHTT | |
| SCHEMBL30857895 | 0.72 | LMNA (0.36) | NQO2PRNPNPSR1LMNAHPGD | |
| SCHEMBL2999406 | 0.70 | NQO2 (0.37) | NQO2LMNAHPGDALDH1A1 | |
| SCHEMBL14493608 | 0.69 | CYP11B1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4416141-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064880-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | NQO2 3129/4885PRNP 285/4885NPSR1 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.